La cadena de opciones muestra datos clave de las opciones de acciones de Eterna Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Eterna Therapeutics..

Eterna Therapeutics (NASDAQ:ERNA) Bolsa, Cadena de Opciones

Eterna Therapeutics

Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.

Eterna Therapeutics Inc

ISH $ ULTRASRT BND ETF USD ACC

ISH ULTRASRT BND ETF USD ACC ETF

<p>Jefferies  analyst Omar Nokta   maintains Safe Bulkers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SB#NYSE">SB</a>) with a Buy and maintains $6 price target.</p>


News

Price Target

Analyst Ratings

Jefferies Maintains Buy on Safe Bulkers, Maintains $6 Price Target

<p>Reviva Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVPH#NASDAQ">RVPH</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 47.92 percent increase over losses of $(0.48) per share from the same period last year.</p>


Earnings

Earnings Beats

RVPH

Reviva Pharmaceuticals Q3 2024 GAAP EPS $(0.25) Beats $(0.26) Estimate

<p>Nova Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVFY#NASDAQ">NVFY</a>) reported quarterly losses of $(0.72) per share. This is a 13.25 percent increase over losses of $(0.83) per share from the same period last year.  The company reported $2.62 million in sales this quarter. This is a 5.65 percent increase over sales of $2.48 million the same period last year.</p>


NVFY

Nova Lifestyle Q3 EPS $(0.72) Up From $(0.83) YoY, Sales $2.62M Up From $2.48M YoY

Hedge Funds

General

FLUT

SPOT

ValueAct Holdings' Q3 2024 13F Filing Reveals Full Exits From Spotify, Fiserv, KKR & Co., New York Times With 1.34M Shares, And Flutter Entertainment

COLL

COLLEGIUM PHARMACEUTICAL Announced That Health Canada Has Approved Its Drug Jornay-PM For The Treatment Of ADHD In Children

<p><strong>Palantir Technologies Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are trading higher in Thursday&#8217;s after-hours session after the company announced it will transfer its stock listing <a href="https://www.benzinga.com/pressreleases/24/11/b41988795/palantir-announces-transfer-of-stock-exchange-listing-to-nasdaq">to the Nasdaq</a>.</p>
<p><strong>What Happened:</strong> After the market close on Thursday, Palantir announced that it would transfer the listing of its Class A common stock from the New York Stock Exchange to the Nasdaq Global Select Market.</p>
<p>Palantir said it expects to begin trading as a Nasdaq-listed company on Nov. 26. The stock will continue to trade under the ticker symbol &#8220;PLTR.&#8221;</p>
<p>&#8220;Upon transferring, Palantir anticipates meeting the eligibility requirements of the Nasdaq-100 Index,&#8221; the company said.</p>
<p><strong>Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41984278/jim-simons-renaissance-technologies-shifts-gears-microsoft-in-tesla-out-palantir-on-top">Jim Simons&#8217; Renaissance Technologies Shifts Gears: Microsoft In, Tesla Out, Palantir On Top</a></strong></p>
<p>Palantir has been one of the hottest stocks of the year, having gained approximately 245% year-to-date, driven by the company&#8217;s positioning in the <a href="http://benzinga.com/topic/ai">AI</a> space. </p>
<p>Palantir shares really took off at the beginning of November after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/41730179/palantir-q3-earnings-revenue-beat-eps-beat-customers-up-39-raises-guidance-results-driven-by-unrele">strong quarterly results</a> driven by&nbsp;"unrelenting" AI demand. </p>
<p>Revenue jumped 30% year-over-year on continued strength in the U.S. customer count grew 39% year-over-year after the company closed 104 deals worth over $1 million during the quarter.</p>
<p>"The growth of our business is accelerating, and our financial performance is exceeding expectations as we meet an unwavering demand for the most advanced artificial intelligence technologies from our U.S. government and commercial customers,&#8221;&nbsp;<strong>Alex Karp</strong>, co-founder and CEO of Palantir, said in a letter to shareholders.</p>
<p><strong>PLTR Price Action:</strong> Palantir shares were up 3.87% in after-hours, trading at $61.47 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><em>Photo: Shutterstock.</em></p>


After-Hours Center

Movers

Tech

PLTR

Palantir Stock Is Rising After The Bell: What's Going On?

Trading Ideas

GOOG

GOOGL

Pershing Square Capital's Q3 2024 13F Filing Reveals Reduced Stakes In Hilton Worldwide By 18% To 7.37M Shares, Chipotle Mexican Grill By 8%, Restaurant Brands Intl By 1% To 23.0M Shares, And Alphabet Class C And Class A By 9%

Pershing Square Capital's Q3 2024 13F Filing Shows New Stakes In Brookfield Corp With 25.88M Shares, Nike With 13.24M Shares, And Seaport Entertainment Group With 2.09M Shares Each In Common Stock And Rights

RBLX

ValueAct Holdings' Q3 2024 13F Filing Indicates Increased Stakes In Walt Disney By 22% To 7.46M Shares And Roblox By 341% To 10.14M Shares

LLYVA

LLYVK

ValueAct Holdings' Q3 2024 13F Filing Shows New Stakes In Meta Platforms With 211.5K Shares, Live Nation Entertainment With 1.01M Shares, Visa With 373.6K Shares, Liberty Media Corp Series C With 1.34M Shares, And Liberty Media Corp Series A With 671.8K Shares

<p>The loss is primarily attributable to a non-cash change in fair value of warrant liabilities related to common share price and warrant price appreciation during the quarter, production restart related operating expenses, and interest expense.</p>


Sable Offshore Reports Q3 Net Income Of $(255.6)M

<p>Marker Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRKR#NASDAQ">MRKR</a>) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.39) by 33.33 percent.  The company reported quarterly sales of $1.926 million which beat the analyst consensus estimate of $1.000 million by 92.60 percent.  This is a 647.65 percent increase over sales of $257.606 thousand the same period last year.</p>


MRKR

Marker Therapeutics Q3 2024 GAAP EPS $(0.26) Beats $(0.39) Estimate, Sales $1.926M Beat $1.000M Estimate

<p>Telsey Advisory Group  analyst Dana Telsey   maintains Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) with a Market Perform and maintains $2 price target.</p>


LVLU

Telsey Advisory Group Maintains Market Perform on Lulus Fashion Lounge, Maintains $2 Price Target

XWEL

XWELL Q3 Revenue $8.4M Up From $7.5M YoY

NNOX

NVDA

RXRX

Nvidia 13F Shows Decreased Stake In Arm Holdings By 13% From 320,823 To 280,411 Shares; Decreased Stake In Recursion Pharmaceuticals By 12% From 57,797 To 50,784 Shares; Decreased Stake In Nano X Imaging Ltd By 17% From 437 To 362 Shares

Earnings Misses

POET

POET Technologies Q3 2024 GAAP EPS $(0.20) Misses $(0.090) Estimate

Contracts

Eaton Says It Has Been Selected By MDA Space To Deliver High-performance Propellant Storage Tanks

SERV

SOUN

Nvidia 13F Shows Increased Stake In Serve Robotics Inc By 308% From 7,267 To 29,629 Shares; Increased Stake In SoundHound AI By 18% From 6,836 To 8,065 Shares

WIIM

OKLO

Oklo shares are trading lower. The company reported Q3 financial results.

<p>Telsey Advisory Group  analyst Dana Telsey   maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Outperform and raises the price target from $183 to $190.</p>


DECK

Telsey Advisory Group Maintains Outperform on Deckers Outdoor, Raises Price Target to $190

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Intuitive Surgical</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/isrg-stock-quote/"><strong>ISRG</strong></a>) stock is getting a boost on Friday as investors celebrate <a href="https://finance.yahoo.com/news/intuitive-announces-fda-clearance-fifth-203000634.html">clearance of the da Vinci 5</a> from the U.S. Food and Drug Administration (FDA).</p>



<p>Da Vinci 5 is the next generation of Intuitive Surgical&rsquo;s multiport robotic system that has been used in more than 7 million procedures. The newest version brings with it increased performance, an enhanced 3D imaging system and new Force Feedback technology.</p>



<p>Myriam J. Curet, M.D., Chief Medical Officer of Intuitive Surgical, said the following about the da Vinci 5:</p>




<p>&ldquo;We strive to provide customers with technology that meets their needs and solves important problems [&hellip;] We intend to launch da Vinci 5 more broadly in the U.S. and globally after we learn from and work with an initial smaller number of customers directly.&rdquo;</p>




<p>Investors looking for more details about the da Vinci 5 launch will get them on Monday. The company plans to hold a conference call before markets open that day to discuss its plans.</p>



<h2>How This Affects ISRG Stock Today</h2>



<p>ISRG stock started off normal trading hours this morning with more than 582,000 shares traded. The company&rsquo;s daily average trading volume is about 1.6 million shares.</p>



<p>ISRG stock is up 1.3% as of Fridya morning.</p>



<p>Investors can check out more of the latest stock market stories today below!</p>



<p>We have all of the hottest stock market news worth reading about on Friday! Among that is what has shares of <strong>Rivian</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rivn-stock-quote/"><strong>RIVN</strong></a>), <strong>Kopin&nbsp;</strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/kopn-stock-quote/"><strong>KOPN</strong></a>) and <strong>Eterna Therapeutics</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/erna-stock-quote/"><strong>ERNA</strong></a>) stock moving today. All of that info is ready to go at the following links!</p>



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/03/piper-sandler-just-raised-its-price-target-on-rivian-rivn-stock/">Piper Sandler Just Raised Its Price Target on Rivian (RIVN) Stock</a></li>



<li><a href="https://investorplace.com/2024/03/why-is-kopin-kopn-stock-down-15-today/">Why Is Kopin (KOPN) Stock Down 15% Today?</a></li>



<li><a href="https://investorplace.com/earning-results/2024/03/erna-stock-earnings-eterna-therapeutics-for-q4-of-2023/">ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023</a></li>
</ul><p><em>On the date of publication, William White&nbsp;did not hold (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/03/isrg-stock-alert-the-fda-is-giving-intuitive-surgical-a-big-boost/">ISRG Stock Alert: The FDA Is Giving Intuitive Surgical a Big Boost</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ISRG Stock Alert: The FDA Is Giving Intuitive Surgical a Big Boost

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Eterna Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/erna-stock-quote/"><strong>ERNA</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Eterna Therapeutics reported earnings per share of -$1.14.</li><li>The company reported revenue of $17,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/03/erna-stock-earnings-eterna-therapeutics-for-q4-of-2023/">ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q4 2023

Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Eterna Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/erna-stock-quote/"><strong>ERNA</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Eterna Therapeutics reported earnings per share of -$1.23.</li><li>The company reported revenue of $47,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/erna-stock-earnings-eterna-therapeutics-for-q1-of-2024/">ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Eterna Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/erna-stock-quote/"><strong>ERNA</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Eterna Therapeutics reported earnings per share of -$1.02.</li><li>The company reported revenue of $47,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/erna-stock-earnings-eterna-therapeutics-for-q2-of-2024/">ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q2 2024

Eterna Therapeutics ( ($ERNA) ) has issued an update. Eterna Therapeutics Inc. has entered into an exclusive licensing and collaboration agreement ...

Eterna Therapeutics Strikes Key Deal for Disease-Fighting Tech

Eterna (ERNA) Therapeutics announced the completion of a comprehensive financial restructuring of the Company with the aim to accelerate its develo...

Eterna completes strategic financial restructuring

Eterna Therapeutics regains Nasdaq compliance

Eterna (ERNA) Therapeutics has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock ...

Eterna regains compliance with Nasdaq

AGRX

AMPE

APTO

AQMS

AREC

ASTS

ATNM

AULT

AXDX

AYRO

BLRX

BZFD

CMCL

CTAS

CWCO

DARE

DCTH

DLNG

DNMR

DOMH

DOYU

DTIL

ERNA

ESLT

GLPG

GREE

HEPS

IDEX

ISRG

ITRM

KOPN

LGMK

LITB

MAXN

MDAI

NCNO

NVVE

OGEN

ORGS

OUST

PAYS

PAYX

PLBY

REKR

RIVN

RKDA

SMTC

STIX

TIVC

VIOT

VRNT

VSTM

VUZI

WPRT

XELA

XXII

Financing

Press Releases

Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing

Management

Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer

Health Care

Markets

Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on the Development of a mRNA-Engineered iPSC Line which Mimics Native B2M Expression, via Targeted Insertion of HLA-E at the B2M Locus

Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases

Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success

Comments

Eterna Therapeutics

Eterna Therapeutics (ERNA) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL